71 completed, 14 terminated, 13 unknown, 9 withdrawn. 41 Phase 4, 27 Phase 2, 19 Phase 3, 17 Not applicable, 15 Phase 1.
Follow Eplerenone: new trials by email Literature Review of Eplerenone trials Research Report on Eplerenone
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Reducing Arterial Inflammation Using Eplerenone and Statins in HIV Eplerenone, Placebo - HIV (Human Immunodeficiency Virus), Cardiovascular Diseases (CVD) | Phase 2 / Phase 3 | Not yet recruiting | Massachusetts General Hospital | 124 | 2027-03-01 | 2026-10-23 |
| Cardiac Improvement by Eplerenone Among Patients Under Cyclosporine or Tacrolimus for Kidney Transplantation. Eplerenone - Kidney Transplantation | Phase 3 | Not yet recruiting | Central Hospital, Nancy, France | 132 | 2027-02-01 | 2026-09-18 |
| Eplerenone and IOP in Healthy Adults Eplerenone, Microcrystalline Cellulose NF (placebo) - Intraocular Pressure (IOP), Healthy Adult | Phase 1 | Not yet recruiting | University of Florida | 30 | 2026-10-01 | 2026-08-31 |
| Early Aldo Blockade in Subclinical PA Eplerenone, Placebo - Subclinical Primary Aldosteronism | Phase 2 / Phase 3 | Not yet recruiting | Xinjiang Medical University | 880 | 2026-08-01 | 2026-07-27 |
| Cardiac Effects of Mineralocorticoid Receptor Antagonism After Hypertensive Disorders of Pregnancy Eplerenone 100 mg daily, Chlorthalidone 25 mg daily, Potassium Placebo - Hypertension | Phase 2 | Recruiting | Massachusetts General Hospital | 90 | 2026-03-20 | 2026-10-20 |
| Swedish Cardiac And Renal Failure Study-1 Eplerenone - HFrEF - Heart Failure With Reduced Ejection Fraction, Chronic Kidney Disease | Phase 2 | Recruiting | Karolinska Institutet | 40 | 2026-02-01 | 2026-02-24 |
| MR and Inflammation After Preeclampsia Eplerenone - Preeclampsia, Preeclampsia Postpartum | Early Phase 1 | Active not recruiting | Anna Stanhewicz, PhD | 40 | 2025-12-17 | 2026-01-16 |
| Vascular Effects of High-Salt After Preeclampsia Eplerenone - Preeclampsia, Preeclampsia Postpartum | Early Phase 1 | Recruiting | Anna Stanhewicz, PhD | 40 | 2025-01-02 | 2026-02-13 |
| Evaluation of Vamorolone Mineralocorticoid Receptor Antagonism in Healthy Subjects Vamorolone, Eplerenone, Fludrocortisone - Pharmacodynamic | Phase 1 | Completed | Santhera Pharmaceuticals | 30 | 2024-06-05 | 2025-09-11 |
| Role of Eplerenone in Reducing Recurrence of Atrial Fibrillation in Patient With Structural Heart Disease Eplerenone - Paroxysmal Atrial Fibrillation | Phase 4 | Not yet recruiting | Assiut University | 100 | 2024-02-01 | 2023-12-13 |
| Therapy to Maintain Remission in Dilated Cardiomyopathy Other - Heart Failure, Cardiomyopathy, Dilated | Not applicable | Unknown | Imperial College London | 50 | 2023-12-02 | 2024-09-19 |
| Optimal Medical Treatment of Difficult-to-treat Hypertension Phase C: Eplerenone, Phase C: Spironolactone, Phase C: Torasemide - Hypertension | Phase 4 | Unknown | National Institute of Cardiology, Warsaw, Poland | 2500 | 2023-10-20 | 2024-02-23 |
| The Predictive Role of Urinary Proteomics in Blood Pressure Response of Obese Hypertensive Treated With Irbesartan or Eplerenone. Irbesartan 150mg, Eplerenone 25 mg - Primary Hypertension, Obesity | Not applicable | Unknown | Hippocration General Hospital | 50 | 2023-09-01 | 2024-01-17 |
| Mineralocorticoid Receptor, Coronary Microvascular Function, and Cardiac Efficiency in Hypertension Eplerenone, Chlorthalidone, Potassium - Hypertension, Left Ventricular Hypertrophy | Phase 4 | Recruiting | Brigham and Women's Hospital | 75 | 2023-08-25 | 2026-04-06 |
| Eplerenone as a Supplement to Epidural Steroid Injections Eplerenone 50 Mg Tab, Placebo Oral Tablet - Degenerative Intervertebral Discs, Sciatic Radiculopathy | Phase 4 | Withdrawn | University of Cincinnati | 2023-06-01 | 2023-03-17 | |
| Unilateral Primary Aldosteronism, Mineralocorticoid Antagonists Versus Surgical Treatment Unilateral adrenalectomy, Medical treatment (eplerenone) - Primary Hyperaldosteronism Due to Adrenal Adenoma | Not applicable | Recruiting | Göteborg University | 80 | 2023-04-28 | 2025-04-06 |
| Eplerenone, Aflibercept and Topical Nepafenac Serous Foveal Deta Chment in Central Serous Chorioretinopathy Eplerenone , Intravitreal Aflibercept and Topical nepafenac therapy - Central Serous Chorioretinopathy | Completed | Dar El Oyoun Hospital | 16 | 2023-02-28 | 2023-05-06 | |
| Effect of Eplerenone on Novel Biomarkers of Mineralocorticoid Receptor Activation (ENOVA) Placebo, Eplerenone 50mg - Hypertension | Phase 4 | Withdrawn | University of Michigan | 2023-02-01 | 2023-02-21 | |
| Cardiovascular Manifestations of MR Activation in Primary Aldosteronism: Pilot Clinical Study Eplerenone - Primary Aldosteronism, Hypertension | Phase 4 | Recruiting | Brigham and Women's Hospital | 40 | 2022-12-15 | 2026-10-15 |
| Polydiuretic Therapy for HFpEF, a Randomised Controlled Trial Low dose combination polydiuretic therapy, Comparator monotherapy empagliflozin - Heart Failure With Preserved Ejection Fraction | Phase 4 | Terminated | The George Institute | 3 | 2022-10-01 | 2024-11-21 |
Showing 20 of 123. Sign in to see all of them.
Hypertension (28) · Heart Failure (14) · Hyperaldosteronism (8) · Renal Insufficiency, Chronic (7) · Central Serous Chorioretinopathy (6) · Essential Hypertension (6) · Metabolic Syndrome (5) · Obesity (5) · Cardiomyopathies (4) · Diabetes Mellitus, Type 2 (4) · Hypertrophy, Left Ventricular (4) · Diabetes Mellitus (3) · Diabetic Nephropathies (3) · Heart Failure, Diastolic (3) · Kidney Failure, Chronic (3)
Brigham and Women's Hospital (10) · Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (8) · Massachusetts General Hospital (4) · Bayer (3) · Central Hospital, Nancy, France (3) · Radboud University Medical Center (3) · Vanderbilt University (3) · Anna Stanhewicz, PhD (2) · AstraZeneca (2) · Biolab Sanus Farmaceutica (2) · Eli Lilly and Company (2) · Hippocration General Hospital (2) · Lene Boesby (2) · Novartis Pharmaceuticals (2) · Pfizer (2)
United States (50) · Netherlands (12) · France (9) · Germany (9) · United Kingdom (8) · Canada (7) · Denmark (7) · Sweden (7) · Greece (6) · Japan (6) · Spain (5) · Australia (4) · Hungary (4) · Poland (4) · Russia (4)
Gail K Adler, MD, PhD (4) · Anna Reid-Stanhewicz, PhD (2) · Deepen Patel, M.D., CCFP (2) · James M Luther, MD (2) · A.H. van den Meiracker, MD, PhD (1) · Adam P Bress, PharmD, MS (1) · Anand Vaidya, MD (1) · Anand Vaidya, MD MMSc (1) · Andre J Witkin, MD (1) · Andrea Haas, MD (1) · Andrzej Tykarski, Prof (1) · Anita Deswal, MD MPH MBBS (1)
PMID 33107592, PMID 40522203, PMID 24107737, PMID 33586138, PMID 39082471, PMID 10450601, PMID 10678860, PMID 10851208, PMID 10908222, PMID 10940788, PMID 11208620, PMID 11422885, PMID 11927799, PMID 12119802, PMID 12923400, PMID 15738343, PMID 16376782, PMID 16391172, PMID 16533484, PMID 17488800, PMID 17494787, PMID 17921053, PMID 1798888, PMID 18195160, PMID 18394706, PMID 18404673, PMID 18426998, PMID 18458174, PMID 18849604, PMID 19047577, PMID 19351633, PMID 19398668, PMID 19464421, PMID 19738158, PMID 19850207, PMID 20016520, PMID 20116803, PMID 20117403, PMID 20299607, PMID 20348438, PMID 20388647, PMID 20411620, PMID 21073363, PMID 21624734, PMID 21807324, PMID 21940729, PMID 21986283, PMID 22017794, PMID 22073219, PMID 22801444
2015 (3), 2008 (1), 2017 (1), 2019 (1), 2025 (1), K23HL128909 (1), K24HL103845 (1), R01DK096994 (1), R01HL109634 (1), R01HL181150 (1), T32HL007609 (1)